



29 November 2019

**Notice under Section 708AA of the Corporations Act 2001 (Cth) – Cleansing Notice**

Sienna Cancer Diagnostics Limited, (ASX:SDX) (“Sienna” or “the Company”), announced a non-renounceable rights issue to 'Eligible Shareholders' on 29 November 2019, being a proposed issue on the basis of 1 fully paid ordinary share (**New Share**) for every 4 fully paid ordinary shares held as at 4 December 2019 (**Record Date**), at an issue price of 3.5 cents per New Share to raise up to approximately \$2.5 million (before costs) by the issue of up to approximately 72 million New Shares (**Rights Issue Offer**). Eligible shareholders are those shareholders who are, as at 7.00pm AEST on the Record Date, registered with a registered address situated in Australia or New Zealand.

In accordance with section 708AA(2)(f) of the *Corporations Act 2001 (Cth)* (**the Act**), the Company gives notice that:

- (a) The New Shares will be offered for issue without disclosure to investors under Part 6D.2 of the Act;
- (b) This notice is given by the Company under section 708AA(2)(f) of the Act;
- (c) As at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) section 674 of the Act;
- (d) As at the date of this notice, there is no information:
  - (i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules of ASX; and
  - (ii) that investors and their professional advisers would reasonably require, and would reasonably expect to find in a disclosure document, for the purpose of making an informed assessment of:
    - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
    - (B) the rights and liabilities attaching to the New Shares.
- (e) The issue of the New Shares may affect the control of the Company.

Assuming that all the shares offered under the Rights Issue Offer are subscribed, the affect of the Rights Issue Offer on the total issued shares would be as follows:

<b>Issued Shares</b>	<b>Shares</b>
Total issued capital of the Company as at the Record Date	289,055,171
Number of New Shares offered under the Rights Issue Offer (assuming maximum number of shares are issued under the Rights Issue Offer)	72,263,793
<b>Total issued capital of the Company at completion of the Rights Issue Offer (excluding the 47,348,164 shares to be issued pursuant to the Placement, also announced on 29 November 2019)</b>	<b>361,318,964</b>

Investors should note the following:

- If eligible shareholders do not take up all of their entitlements under the offer, the share interests of those shareholders will be diluted;
- The proportional interests of shareholders with registered addresses outside Australia and New Zealand will be diluted because those shareholders are not entitled to participate in the Rights Issue Offer; and
- Should the Company's major shareholders subscribe for their full entitlement under the Rights Issue Offer, there will not be any material impact on the control of the Company following the issue of shares under the Rights Issue Offer.

Further details about the Rights Issue Offer were announced via the ASX announcement platform on 29 November 2019.

For further information, please view our website ([www.siennadiagnostics.com.au](http://www.siennadiagnostics.com.au)) or contact the Company on (03) 8288 2141 between the hours of 9.00am and 5.00pm AEST Monday to Friday.

On behalf of the Board of the Company,

A handwritten signature in black ink, appearing to read 'Tony Di Pietro', with a horizontal line extending to the left.

Tony Di Pietro  
Company Secretary  
Sienna Cancer Diagnostics Limited.